When was Casma Therapeutics founded?

Casma Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Casma Therapeutics located?

Casma Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Casma Therapeutics have?

As of Mar 01, 2026, the latest employee count at Casma Therapeutics is 10 - 49.

Is Casma Therapeutics a funded company?

Casma Therapeutics is a funded company, having raised a total of $154M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 03, 2018.

When was the latest funding round of Casma Therapeutics?

Casma Therapeutics' latest funding was a $***** Grant (prize money) round on Mar 10, 2026, with participation from 1 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $741M in funding in 2026 to date.

Where does Casma Therapeutics rank among its competitors?

Casma Therapeutics ranks 109th amongst 278 active competitors, of which 78 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Casma Therapeutics, which secured $7.6M in Mar, 2026.

Who are the top competitors of Casma Therapeutics?

Casma Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, Casma Therapeutics secured the most recent funding round in March, 2026.

Casma Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Casma Therapeutics is developing therapies for treating rare genetic disorders. They are focused on autophagy of rare genetic diseases which helps in restoring cellular balance and reversing the course of the disease. The technology enables initiation, the formation of the autophagosome, fusion with lysosomes, and lysosomal biogenesis.

Website: www.casmatx.com/
Social
Email ID: *****@casmatx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series C

Total Funding

$154M in 4 rounds

Latest Funding Round

Grant (prize money), Mar 10, 2026, $*****

Investors

Third Rock Ventures & 13 more

Ranked

109^th among 278 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

BridgeBio & 312 more

View Casma Therapeutics' full profile

Casma Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CASMA THERAPEUTICS INC. CIN: 820726146 , United States, Active	Dec 26, 999	-	8 (As on Dec 31, 2024)	-

Casma Therapeutics has raised a total funding of $154M over 4 rounds. Its first funding round was on May 03, 2018. Its latest funding round was a Grant (prize money) round on Mar 10, 2026 for $*****. 1 investor participated in its latest round. Casma Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Casma Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 10, 2026	4458254	Grant (prize money)	1341827	8035197	7627590	3499191
Nov 15, 2022	4554230	Series C	5594802	8948579	5278998	Eventide Asset Management & 4 more
Sep 10, 2020	4328783	Series B	6274864	7159507	The Column Group & 3 more	7105267

Access funding benchmarks and valuations. Sign up today!

View details of Casma Therapeutics's funding rounds and investors

Casma Therapeutics' employee count trend

Casma Therapeutics has 10 - 49 employees as of Mar 26. Here is Casma Therapeutics's employee count trend over the years:

Employee count trend for Casma Therapeutics

Uncover Casma Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Casma Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Casma Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	T. Rowe Price, Fidelity Investments & 9 others	69/100
109th	Casma Therapeutics 2017, Cambridge (United States), Series C	Developer of therapies for treating rare genetic disorders	$154M	The Column Group, Schroders & 12 others	42/100